Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology.

Joseph TherriaultMarcel S WooGemma SalvadóJohan GobomThomas K KarikariShorena JanelidzeStijn ServaesNesrine RahmouniCécile TissotNicholas J AshtonAndréa Lessa BenedetLaia Montoliu-GayaArthur C MacedoFiroza Z LussierJenna StevensonPaolo VitaliManuel A FrieseGassan MassarwehJean-Paul SoucyTharick A PascoalErik StomrudSebastian PalmqvistNiklas Mattsson-CarlgrenSerge GauthierHenrik ZetterbergOskar HanssonKaj BlennowPedro Rosa-Neto

Published in: Molecular neurodegeneration (2024)

Our results suggest that while similar overall, immunoassay-based p-tau biomarkers are slightly superior to antibody-free mass spectrometry-based p-tau biomarkers. Future work is needed to determine whether the potential to evaluate multiple biomarkers within a single run offsets the slightly lower performance of antibody-free mass spectrometry-based p-tau quantification.

Keyphrases

mass spectrometry
cerebrospinal fluid
liquid chromatography
gas chromatography
capillary electrophoresis
high performance liquid chromatography
high resolution
sensitive detection
tandem mass spectrometry
cognitive decline
risk assessment
current status
climate change
human health
solid phase extraction